- Home
- GALT vs HRTX Comparison
GALT vs HRTX Comparison
Compare GALT & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- HRTX
- Stock Information
- Founded
- GALT 2000
- HRTX 1983
- Country
- GALT United States
- HRTX United States
- Employees
- GALT N/A
- HRTX N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- HRTX Health Care
- Exchange
- GALT Nasdaq
- HRTX Nasdaq
- Market Cap
- GALT 232.3M
- HRTX 276.1M
- IPO Year
- GALT N/A
- HRTX 1987
- Fundamental
- Price
- GALT $3.57
- HRTX $1.33
- Analyst Decision
- GALT Strong Buy
- HRTX Strong Buy
- Analyst Count
- GALT 3
- HRTX 2
- Target Price
- GALT $6.00
- HRTX $4.50
- AVG Volume (30 Days)
- GALT 299.1K
- HRTX 2.2M
- Earning Date
- GALT 08-14-2025
- HRTX 08-08-2025
- Dividend Yield
- GALT N/A
- HRTX N/A
- EPS Growth
- GALT N/A
- HRTX N/A
- EPS
- GALT N/A
- HRTX N/A
- Revenue
- GALT N/A
- HRTX $149,694,000.00
- Revenue This Year
- GALT N/A
- HRTX $12.08
- Revenue Next Year
- GALT N/A
- HRTX $12.57
- P/E Ratio
- GALT N/A
- HRTX N/A
- Revenue Growth
- GALT N/A
- HRTX 9.78
- 52 Week Low
- GALT $0.73
- HRTX $1.04
- 52 Week High
- GALT $4.41
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- GALT 58.06
- HRTX 28.25
- Support Level
- GALT $3.55
- HRTX $1.31
- Resistance Level
- GALT $3.90
- HRTX $1.47
- Average True Range (ATR)
- GALT 0.32
- HRTX 0.11
- MACD
- GALT -0.04
- HRTX -0.04
- Stochastic Oscillator
- GALT 41.67
- HRTX 19.72
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.